In the long run every single small biotech will fail IMHO.
Our market is just not big enough to support them properly (they are highly capital intensive) and the government does not offer significant incentive and capital protection for venture capitalists in this country.
Big Super never touches it for these reasons, and it shows.
Care to take a look at the previous stats on the failure rate?
The exception being those that are capitalised properly from the outset
And have a significant "shareholder" to support them through think and thin.
CSL (government) and COH (PacDun) being prime examples.
Its a shocker of a sector for share investors and Malc et al refuses to do anything about the situation.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)